Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CN NMPA Seeks Opinions on Inclusion in 30-Day Channel for Innovative Drug Clinical Trial Review & Approval Applications
Recommend 34 Positive 61 Negative 19 |
||||
|
||||
|
China's National Medical Products Administration (NMPA) is publicly seeking opinions on the Announcement on Matters Related to the Optimization of Innovative Drug Clinical Trial Review and Approval (Draft for Comments). The announcement proposes that applications for inclusion in the 30-day channel for innovative drug clinical trial review and approval should be for Category 1 innovative drugs (traditional Chinese medicine, chemical drugs, and biological products). Their application materials also have to be submitted as required and meet a range of conditions. For instance, the drugs should be key innovative drugs with national support. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
